arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Bolt Biotherapeutics, Inc.

BOLT
$3.61 ▼ -0.02 (-0.55%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
27 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
15
Health
Poor
Bearish
auto_awesome

Analytical Summary

Bolt Biotherapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $6.1M
Dividend Yield
Revenue Growth -99.7%
Op. Margin None
ROIC -52.3%
FCF / Share $-3.87
Trailing P/E
Price / Book 0.6x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$5.00K
↓ -99.7%
Net Income Profit after all expenses
$-7.72M
↑ +9.8%
Operating Margin Operating profit as % of sales
-283.4%
↑ +20.2% 0th
FCF / Share Free cash flow per share
$-3.87
↑ +22.7%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
0
Returns
6
Cash Quality
73

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 27 quarters